NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 13 April 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Stephen Smith (Vice-chair) Present for all items
3. Martin Bradley Present for all items
4. Professor Sofia Dias Present for all items
5. Professor Rachel Elliott Present for all items
6. Dr Andrew Hitchings Items 5 to 5.2.2
7. Dr Robert Hodgson Present for all items
8. Dr Philip Mallender Present for all items
9. Professor David Meads Present for all items
10. Giles Monnickendam Present for all items
11. Dr Nathan Moore Items 1 to 4.3.2
12. Dr Malcolm Oswald Present for all items
13. Dr Rebecca Payne Present for all items
14. Sara Payne Items 1 to 4.2.1
15. Carole Pitkeathley Present for all items
16. Dr Raju Reddy Present for all items

NICE staff (key players) present

Linda Landells, Associate Director Items 1 to 4.3.2

Jasdeep Hayre, Associate Director Items 5 to 5.2.2

Kate Moore, Project Manager Present for all items

Rufaro Kausi, Heath Technology Assessment Adviser Items 5 to 5.2.2

Anita Sangha, Heath Technology Assessment Analyst Items1 to 4.3.2

Cara Gibbons, Heath Technology Assessment Analyst Items 5 to 5.2.2

External assessment group representatives present

Amy Grove, Warwick Evidence Items 1 to 4.2.1

Hesam Ghiasvand, Warwick Evidence Items 1 to 4.2.1

Isaac Mackenzie, BMJ Group Items 5 to 5.1.3

Nicole Downes, BMJ Group Items 5 to 5.1.3

Clinical & Patient experts present

Antionette Carr, Patient expert, nominated by Myeloma UK Items 1 to 4.2.1

Shelagh McKinley, Patient expert, Head of Patient Advocacy, nominated by Myeloma UK, Items 1 to 4.2.1

Dr Rakesh Popat, Consultant Haematologist, clinical expert nominated by GlaxoSmithKline, Items 1 to 4.2.1

Dr Karthik Ramasamy, Consultant Haematologist & clinical expert nominated by GlaxoSmithKline, Items 1 to 4.2.1

## Minutes

### Introduction to the meeting

* 1. The chair Dr Stephen Smith welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr Bernard Khoo, Professor Chris Parker, Christopher Herring, Dr Guy Makin, Dr Ivan Koychev and Professor John Watkins.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 16 March 2023.

### Appraisal of belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from GlaxoSmithKline.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10568/documents).

* + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Carole Pitkeathley, Dr Raju Reddy and Dr Robert Hodgson.
  1. Part 2a – Closed session (members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (company representatives, experts, and external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10568>

### Appraisal of rimegepant for treating or preventing migraine [ID1539]

* 1. Part 1 – Open session
     1. The chair Dr Megan John welcomed the external assessment group representatives, members of the public and company representatives from Pfizer.
     2. The chair asked all committee members, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10839/documents).

* + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10839>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 11 May 2023.